Marshall Wace, LLP Arcutis Biotherapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.84 - $4.82 $4.08 Million - $10.7 Million	-2,216,066 Reduced 95.89%	95,011 $306,000
Q3 2023 Nov 14, 2023	SELL	$5.31 - $10.98 $34,323 - $70,974	-6,464 Reduced 0.28%	2,311,077 $12.3 Million
Q2 2023 Aug 14, 2023	BUY	$7.51 - $15.0 $91,659 - $183,075	12,205 Added 0.53%	2,317,541 $22.1 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $23.6 Million - $39.5 Million	2,305,336 New	2,305,336 $25.4 Million
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $3 Million - $4.52 Million	167,816 New	167,816 $3.21 Million

Q2 2021 Aug 13, 2021	SELL	$24.42 - $34.75 $3.77 Million - $5.36 Million	-154,349 Reduced 91.07%	15,138 $413,000
Q1 2021 May 17, 2021	BUY	$24.47 - $36.98 $2.21 Million - $3.35 Million	90,514 Added 114.61%	169,487 $4.9 Million
Q4 2020 Feb 16, 2021	BUY	$17.82 - $31.73 $1.41 Million - $2.51 Million	78,973 New	78,973 $2.22 Million

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.